Regeneron Pharmaceuticals Inc's third-quarter profit nearly doubled on Thursday, helped by robust demand for its blockbuster drugs Dupixent to treat eczema and eye treatment Eylea.
The company's net profit rose to $1.63 billion, or $14.33 per share, in the quarter ended Sept. 30, from $842.1 million, or $7.39 per share, a year earlier.
Its shares stayed flat in premarket trading.
精彩评论